it’s evident that NNZ2591 is a superior drug. In the recent interview with Hashan, he used Neuren as an example to demonstrate that Aussie biotechs often lack the financials to push through the trials with their assets. In the case of Neuren, rather than focusing on the most promising drug NNZ2591 initially, Neuren had to prioritise Trofinetide as it was more progressed and less financials were required
NEU Price at posting:
$21.22 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)